The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preexistence of CT findings with usual interstitial pneumonia (UIP) pattern correlates to radiation pneumonitis (RP) in non-small cell lung cancer (NSCLC) patients receiving chemoradiotherapy (CRT).
 
Junji Koyama
No Relationships to Disclose
 
Satoru Kitazono
No Relationships to Disclose
 
Ryo Ariyasu
No Relationships to Disclose
 
Masafumi Saiki
No Relationships to Disclose
 
Tomoaki Sonoda
No Relationships to Disclose
 
Yosuke Kawashima
No Relationships to Disclose
 
Natsuki Takano
No Relationships to Disclose
 
Tomoyo Oguri
No Relationships to Disclose
 
Shingo Nishikawa
No Relationships to Disclose
 
Noriko Yanagitani
Consulting or Advisory Role - Chugai Pharma
 
Atsushi Horiike
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer
Research Funding - Chugai Pharma (Inst); MSD Oncology (Inst); Quintiles (Inst)
 
Fumiyoshi Ohyanagi
No Relationships to Disclose
 
Katsunori Oikado
No Relationships to Disclose
 
Takuyo Kozuka
No Relationships to Disclose
 
Makoto Nishio
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)